MDM2 Inhibitor May Improve Response in Acute Myeloid Leukemia

ARIELA KATZ | October 20, 2018
Investigators are hopeful that idasanutlin, a novel small molecule that targets the MDM2 protein, can improve the efficacy of chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML). This agent is being tested in combination with cytarabine, which is commonly used as a first or second salvage therapy in this patient population, in the international phase III MIRROS clinical trial (NCT02545283).

RATIONALE

Idasanutlin inhibits the MDM2 protein, which degrades p53, a known tumor growth suppressor, said Marina Y. Konopleva, MD, PhD, professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston. The drug binds to MDM2 to prevent the inter­action between the 2 proteins, resulting in the ongoing activation of p53 and tumor-cell apoptosis.1

TRIAL DESIGN

The primary endpoint in the MIRROS trial is overall survival (OS) and will be assessed in a subset of the patient population with the gene TP53 wild-type, with OS in the overall population as a secondary endpoint. Assessing the TP53 wild-type population as the primary endpoint is important because idasanutlin’s mechanism of action depends on p53, which is encoded by TP53.
 
About 440 participants are expected to join the trial (NCT02545283). They will be randomized 2:1, idasanutlin with cytarabine versus cytar­abine with placebo. In the experimental arm, 300 mg of idasanutlin will be given orally twice a day in a 28-day treatment cycle (cycle 1). Responding participants may continue with 300 mg once daily (cycles 2 and 3) for 5 consecutive days each 28-day treatment cycle. One g/m2 IV infusion of cytarabine will be given for 5 consecutive days each 28-day treatment cycle.

WHO IS ELIGIBLE?

The trial is currently enrolling patients with relapsed/refractory AML who have experienced 1 or 2 relapses. They also must have received no more than 2 prior induction regimens, and 1 or both must have included cytarabine with an anthracycline.

Konopleva is hopeful that if idasanutlin and cytarabine yield a higher response rate than cytarabine alone in the MIRROS study, the combi­nation could become a standard of care for patients with AML with the TP53 wild-type gene as first or second salvage therapy.
 
REFERENCE
  1. Idasanutlin. Genentech website. biooncology.com/pipeline-molecules/idasanutlin. html. Accessed June 4, 2018.

A version of this article was originally published by OncLive® as “Potency of CAR T-Cell Therapy Investigated in Relapsed/Refractory MCL

 

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Related Articles
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.